Founder and CEO
Ali has more than 25 years of experience in international business, marketing, and sales. In addition to founding Science24Seven and GlobalOvation, Ali advises several biotech, medical device, diagnostic, and pharmaceutical companies. His experience ranges from working with very large multinationals – Johnson & Johnson, Eli Lilly, Novo Nordisk, Vertex Pharmaceuticals, to promising start-ups – 3Derm Systems, Caring In Place, Cellanyx Diagnostics, and Edge Therapeutics. Previously he was the chief marketing officer and vice president of global markets for Innocentive, an Eli Lilly & Company spin-off. There he built the world's first virtual, global scientific community, working with partners in China, India, Russia, and elsewhere. Ali was also the director of marketing and business development for Amazon.com's wireless initiative, Amazon Anywhere—establishing strategic alliances with AT&T, Motorola, Nokia, Sprint, T-Mobile, and other leading wireless companies. At WPP, the world's largest communications services company, Ali served as the account director for Procter & Gamble.
GINA R. KRITCHEVSKY
PARTNER, SCIENTIFIC OFFICER
Dr. Kritchevsky is a leading expert in advanced materials, microelectronics packaging and liquid crystal display technology, optical materials and coatings with a specialty in intellectual property and consults with leading multinational corporations. She previously served as the Chief Technology Officer and Vice President, Technology and Engineering at Nanophase Technologies, Inc. Dr. Kritchevsky was Vice President of Strategic Initiatives for Donnelly Optics Corporation. She also served in various positions with Donnelly Corporation, including Director of Corporate New Business Development. She holds a BS in chemistry and a PhD in material sciences and engineering from MIT. She also is a registered patent agent with expertise in evaluation of intellectual property of advanced materials technology.
Partner, Scientific Officer
Dr. Panetta has over 25 years of experience in drug discovery research and development at Eli Lilly and Company, including IP development for the prevention of bone loss and reabsorption, treatment of diabetes, and neuroprotection with an emphasis on stroke and Alzheimer’s disease. Dr. Panetta's early research efforts led to the discovery of two clinical candidates: tibenelast for asthma and tazofelone for inflammatory bowel disease. Over her career, she has authored more than 88 publications and abstracts, has given over 65 invited lectures and has 33 granted US patents. Dr. Panetta is the former Chief Scientific Officer at the Polycystic Kidney Disease Foundation where she led and directed the foundation’s research strategy and was the key architect of the foundation’s Accelerating Treatments to Patients (ATP) research initiative. Dr. Panetta is co- founder and former Chief Scientific Officer of InnoCentive, an Eli Lilly & Company spinoff company.
Orhan H. Suleiman
Partner, Regulatory Officer
Dr Orhan H. Suleiman, MS, PhD, FAAPM, FHPS, brings to our team a broad range of scientific and regulatory experience regarding the safety and efficacy of drugs and medical devices marketed in the United States. He recently retired from the US Food and Drug Administration (FDA), after 37 years with the federal agency. Most recently he was the Senior Science Policy Advisor in the FDA's Office New Drugs. He served as the FDA representative on the Nuclear Regulatory Commission's Advisory Committee on Medical Use of Isotopes (ACMUI), and represented the Department of Health and Human Services at international meetings sponsored by the Organization of Economic Cooperation and Development’s, the International Atomic Energy Agency, and the International Electro-technical Commission. He worked in the Commissioner’s Office of Counter-terrorism immediately after the September, 2001 anthrax terrorism events, and previously worked in FDA’s Center for Devices and Radiological Health. Prior to coming to the FDA he worked for the Department of Defense, and the State of Florida. He has a BS and MS in Radiological Sciences and received his PhD from the Johns Hopkins School of Hygiene and Public Health. In 1998 he was appointed to FDA's Senior Biomedical Research Service and is a Fellow of the American Association of Physicists in Medicine and the Health Physics Society.
Clayton M. Christensen
Clayton Christensen is the Kim B. Clark Professor of Business Administration at the Harvard Business School, where he teaches one of the most popular elective classes for second year students, Building and Sustaining a Successful Enterprise. He is regarded as one of the world’s top experts on innovation and growth and his ideas have been widely used in industries and organizations throughout the world. A 2011 cover story in Forbes magazine noted that ‘’Everyday business leaders call him or make the pilgrimage to his office in Boston, Mass. to get advice or thank him for his ideas.’’ In 2011 in a poll of thousands of executives, consultants and business school professors, Christensen was named as the most influential business thinker in the world.
Professor Clayton received his B.A. in economics, summa cum laude, from Brigham Young University and an M.Phil. in applied econometrics from Oxford University, where he studied as a Rhodes Scholar. He subsequently received an MBA with High Distinction from the Harvard Business School in 1979, graduating as a George F. Baker Scholar. In 1982 Professor Christensen was named a White House Fellow, and served as assistant to U.S. Transportation Secretaries Drew Lewis and Elizabeth Dole. He was awarded his DBA from the Harvard Business School in 1992, and became a faculty member there the same year, eventually receiving full professorship with tenure in 1998. He holds five honorary doctorates and an honorary chaired professorship at the Tsinghua University in Taiwan.
Prior to his academic career, Clayton worked as a management consultant with BCG in their Boston office and helped co-found Ceramics Process Systems, a Massachusetts-based advanced materials company. He has subsequently helped establish many other successful enterprises, including the innovation consulting firm Innosight, the public policy think tank Innosight Institute, and the boutique investment firm Rose Park Advisors.
Clay is the best-selling author of nine books and more than a hundred articles. His first book, The Innovator’s Dilemma received the Global Business Book Award as the best business book of the year (1997); and in 2011 The Economist named it as one of the six most important books about business ever written. His other articles and books have received the Abernathy, Newcomen, James Madison, and Circle Prizes. Clay is a five-time recipient of the McKinsey Award, given each year to the two best articles published in the Harvard Business Review; and has received the Lifetime Achievement Award from the Tribeca Films Festival (2010).
Clay has served on the Boy Scouts of America for 25 years as a scoutmaster, cubmaster, den leader, troop and pack committee chairman. Born in Salt Lake City, Utah, Clay worked as a missionary for his church in the Republic of Korea from 1971 to 1973, where he learned to speak fluent Korean. He continues to serve in his church in as many ways as he can.
Peter is a Managing Director for Cross Creek Advisors. He joined Cross Creek in 2010 after four years as a Senior Investment Manager for Fort Washington Capital Partners Group, where he assisted in managing its venture and private equity investment portfolios.
Prior to focusing on the investment side of private equity, Peter spent nearly 10 years operating in restructuring and marketing roles for venture and private equity funded companies. His experience includes senior roles at PTC, Ancestry.com, Campus Pipeline and Icon Health and Fitness. Peter received his MBA from the Northwestern Kellogg Graduate School of Management and was a finalist for the Ewing Kauffman Venture Fellows program.
Phillip C. Thomas
Phil has over 25 years experience as a public and private company CEO and has experienced many of the challenges inherent in navigating the difficult process of creating, growing, and sustaining a profitable business. His business experience includes serving as the CEO and Founder of several high tech firms as well as CEO level leadership at a number of public companies.
Prior to his business career, Phil served with distinction for eight years as a Naval Intelligence Officer earning consistent top 1% performance reports, selection for early promotion, and other honors. Phil earned his BA, Political Science from Brigham Young University and took part in additional professional development endeavors including the Masters of Science, Strategic Intelligence Program at the Defense Intelligence Agency and executive development programs at the Stanford and Harvard Business Schools.